K. Abd El-Rahman, MohamedM. Riad, SafaaA. Abdel Gawad, SherifM. Fawaz, EsraaA. Shehata, Mostafa2020-01-222020-01-222015[1] Sean C. Sweetman, Martindale: The Complete Drug Reference (36th edition)- contrast media, 2010, pp. 1327–1348. [2] C. Christiansen, X-ray contrast media-an overview, 2005, pp. 185–187. [3] T.J. Barrs, X-rays and radiopaque drugs, 2005, pp. 2026–2030. [4] H. Katayama, K. Yamaguchi, T. Kozuka, T. Takjashima, P. Seez, K. Matsuura, J. Radiol. 175 (1990) 621–662. [5] Hayam Mahmoud Lotfy, Mona M. Abd el-Moneim Abosen, Mohamed Galal ELBardicy, Drug Test. Anal. 2 (4) (2010) 188–199. [6] F.H. Metwally, M. Abdelkawy, N.S. Abdelwahab, Spectrochim. Acta Part A: Mol. Biomol. Spectrosc. 68 (2007) 1220–1230. [7] María M. De Zan, María S. Cámara, Juan C. Robles, Silvina V. Kergaravat, Héctor C. Goicoechea, Talanta 79 (2009) 762–767. [8] S. Tan, X. Qisu, Chin. J. Pharm. Anal. 11 (1991) 184–185. [9] G.M. Hanna, C.A. Lau-Cam, J. AOAC Int. 79 (1996) 833–838. [10] S.A. Farag, C.E. Wells, Mikrochim. Acta 126 (1–2) (1997) 141–145. [11] S.A. Farag, J. AOAC Int. 78 (2) (1995) 328–333. [12] E.M. Chellquist, W.O. Nelson, H.L. Storflor, J. Pharm. Biomed. Anal. 16 (1) (1997) 39–45. [13] The United States Pharmacopeia and National Formulary, The Official Compendia of Standards. Asian Edition, USP 34-NF 29 The United States Pharmacopeial Convention Inc., Rockvill, MD, 2011, volume 2, 2531. [14] R. Weiss, B. Hsu, L. Wheeler, A. Norman, R.F. Riley, Invest. Radiol. 16 (6) (1981) 517–524. Nov–Dec. [15] A.K.S. Ahmad, M. Abdel Kawy, M. Nebsen, J. Pharm. Biomed. Anal. 30 (2002) 479–489. [16] H.W. Darwish, S.A. Hassan, M.Y. Salem, B.A. El-Zeiny, Spectrochim. Acta Part A: Mol. Biomol. Spectrosc. 113 (2013) 215–223. [17] N.Y. Hassan, E.M. Abdel-Moety, N.A. Elragehy, M.R. Rezk, Spectrochim. Acta Part A: Mol. Biomol. Spectrosc. 72 (2009) 915–921. [18] The United States Pharmacopeia and National Formulary, The Official Compendia of Standards. Asian Edition, USP 30-NF 25 The United States Pharmacopeial Convention Inc., Rockvill, MD, 2007.https://doi.org/https://t.ly/zMnxVMSA Google ScholarThree sensitive, selective, and precise stability indicating methods for the determination of the X-ray contrast agent, diatrizoate sodium (DTA), in the presence of its acidic degradation product (highly cytotoxic 3,5 diamino metabolite) and in pharmaceutical formulation were developed and validated. The first method is a first derivative (D1) spectrophotometric one, which allows the determination of DTA in the presence of its degradate at 231.2 nm (corresponding to zero crossing of the degradate) over a concentration range of 2–24 lg/mL with mean percentage recovery 99.95 ± 0.97%. The second method is the first derivative of the ratio spectra (DD1) by measuring the peak amplitude at 227 nm over the same concentration range as D1 spectrophotometric method, with mean percentage recovery 99.99 ± 1.15%. The third method is a TLC-densitometric one, where DTA was separated from its degradate on silica gel plates using chloroform:methanol:ammonium hydroxide (20:10:2 by volume) as a developing system. This method depends on quantitative densitometric evaluation of thin layer chromatogram of DTA at 238 nm over a concentration range of 4–20 lg/spot, with mean percentage recovery 99.88 ± 0.89%. The selectivity of the proposed methods was tested using laboratory-prepared mixtures. The proposed methods have been successfully applied to the analysis of DTA in pharmaceutical dosage forms without interference from other dosage form additives. The results were statistically compared with the official US pharmacopeial method. No significant difference for either accuracy or precision was observed.enUniversity of Sodium diatrizoate; Derivative spectrophotometry; TLC-densitometry; Stability indicating methodsArticlehttps://doi.org/